Evaluation of Safety and Efficacy of 1550 nm/1927nm Laser on the treatment of rosacea

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250206009

Enrollment

Registered

2025-02-06

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea Rosacea

Interventions

1550 nm/1927nm Laser

Experimental Device

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Thai Male or Female, age 18-65 years old 2. Have erythematoangiectatic or papulopustular rosacea with severity of IGA 1-3 3. Voluntarily agree to be treated with the treatment and comply to the follow-up appointment

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactating women 2. Received treatment for rosacea in 2 weeks prior the study e.g. Metronidazole, Bromonidine, Oxymetazoline, Calcineurin inhibitors, Azelaic acid etc. 3. Received antibiotics within 4 weeks 4. Receive Isotretinoin within 6 months 5. Have dermatitis and/or skin infection on the treatment area 6. Have photosensitivity 7. Received prior treatments with filler, botulinum toxin, PRP, biostimulator, thread or laser withing 6 months 8. Have history of keloid 9. Have psychiatric disorders 10. Cannot comply with the treatment and/or follow-up protocol 11. Do not agree to be photographed for the evaluation 12. Have a certain medical conditions e.g. immunocompromised, HIV/AIDS, cancer etc 13. Received treatment with topical retinoids within 3 months

Design outcomes

Primary

Measure	Time frame
Efficacy of treatment for rosacea baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1,3,6-month after completing treatments IGA (Investigator's Global Assessment) score, red area score measured by Antera, redness measured by VISIA, average level of erythema measured by Mexameter,Safety of treatment baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1,3,6-month after completing treatments adverse event	—

Measure

Time frame

Efficacy of treatment for rosacea baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1,3,6-month after completing treatments IGA (Investigator's Global Assessment) score, red area score measured by Antera, redness measured by VISIA, average level of erythema measured by Mexameter,Safety of treatment baseline, 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1,3,6-month after completing treatments adverse event

—

Secondary

Measure	Time frame
Physician improvement scale 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1,3,6-month after completing treatments Quartile scale,Patient improvement scale 2 weeks after 1st treatment, 2 weeks after 2nd treatment, 1,3,6-month after completing treatments Quartile scale	—

Countries

Thailand

Contacts

Public ContactWoramate Bhorntarakcharoen

Faculty of medicine Siriraj hospital, Mahidol university

rungsima.wan@mahidol.ac.th024197000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026